Azadyne was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon & Mike Southern to commercialise the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin. Azadyne’s groundbreaking work in RNA modification has been supported by investment syndicates led by NCL & Kent Life Sciences and private equity group 24 Haymarket.
Azadyne is a virtual company with a team of experienced pharma industry professionals, which is further supported by consultants and contract research organisations. The company has an office at Canterbury Innovation Centre, Canterbury, Kent.
The ability of azadyne to selectively modify tRNA in situating its targeted small molecules approach allows careful modulation of protein synthesis within targeted cells.
The platform nature of the approach opens it up to treating alternative disease areas and the team are keen to explore such opportunities with potential collaborators. Please get in touch using our contact details if you would like to discuss this further.
Azadyne Board
Dr Jason Rutt
CEO
Jonathan Synett
Director, Chief Investment Officer NCL
Paul Tselentis
Director, CEO 24Haymarket
Prof Stephen Connon
Head of Synthetic Chemistry TCD
Azadyne Team
Dr Jason Rutt
CEO
Dr Tim Bourne
CSO
Prof Vincent Kelly
Head of TCD transgenic facility.
Prof Mike Southern
Medicinal Chemistry TCD
Prof Stephen Connon
Head of Synthetic Chemistry TCD